Guideline-directed medical therapy use, persistence, and cardiovascular outcomes following ST-segment elevation myocardial infarction: a pooled analysis of three randomised trials with external registry validation
In brief
Four-class therapy after STEMI falls from over two-thirds to about half
Among patients treated with PCI for STEMI, 67% to 84% received all four guideline-directed drug classes at discharge, but only 41% to 53% did so five years later. Exploratory analyses linked more drug classes with fewer cardiovascular events, but the study shows an association, not proof that maintaining therapy caused better outcomes. The decline highlights a persistent challenge in long-term treatment.
- Journal
- The Lancet regional health. Europe (Q1)
- Published
- 7 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Daijiro Tomii, Dik Heg, Sylvain Losdat, Miklos Rohla, Jonas D Häner, Lukas Hunziker, et al.
- PMID
- 43032792
- DOI
- 10.1016/j.lanepe.2026.101919
Why clinicians should know about it
- Picked for Internal Medicine (top studies of the week, 22 November 2026): Post-MI medication persistence and cardiovascular outcomes
Abstract
BACKGROUND: Implementation and long-term persistence of guideline-directed medical therapy (GDMT) following ST-segment elevation myocardial infarction (STEMI) remain suboptimal. We assessed the implementation and persistence of four-class GDMT after STEMI and its association with outcomes. METHODS: We performed a patient-level pooled analysis of three randomised trials of patients undergoing percutaneous coronary intervention for STEMI. GDMT was defined by the number of drug classes prescribed (0-4). External validation was conducted using a real-world PCI registry. FINDINGS: The study included 2270 patients from the randomised trials and 5643 from a real-world PCI registry. More than two-thirds of patients received all four GDMT classes at discharge (ranging from 66.9% [398/595] to 83.5% [339/406]), but this proportion declined over 5 years (ranging from 40.5% [408/1008] to 53.1% [276/520]). In exploratory analyses, higher GDMT class at discharge was associated with a lower risk of the composite of cardiovascular death, stroke, or myocardial infarction at 5 years (adjusted HR [95% CI] for class 4 versus 0-2: 0.49 [0.33-0.72]; class 3 versus 0-2: 0.49 [0.28-0.85]). In a time-dependent analysis, higher GDMT class during follow-up was associated with a lower risk of the composite outcome (adjusted IRR [95% CI] for class 4 versus 0-2: 0.71 [0.52-0.95]; class 3 versus 0-2: 0.59 [0.41-0.86]). Similar longitudinal patterns were observed in the real-world PCI registry. INTERPRETATION: Although the majority of patients received all four GDMT classes at discharge after STEMI, this proportion declined during long-term follow-up. In exploratory analyses, higher GDMT class was associated with a lower risk of cardiovascular events. FUNDING: No specific funding was received for the present study. Funding for the individual trials and registry is reported in the Acknowledgements.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.